An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...

Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...

Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...

Shares of Gilead Sciences stock opened at $86.14 on Monday. The business has a fifty day simple moving average of $79.34 and a two-hundred day simple moving average of $72.07. Gilead Sciences has ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $85.21 which represents a slight increase of $0.78 or 0.92% from the prior close of $84.43. The stock opened at ...

Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and ...